Pfizer tops estimates, hikes low end of revenue guidance on strength of Eliquis, other drugs

CNBC reports that Pfizer beat second-quarter earnings expectations and raised the lower end of its full-year revenue guidance. Strength from drugs like Eliquis is driving the boost, though Pfizer is also cutting its full-year COVID product revenue forecast to four billion dollars, down from about five billion previously.

Listen to this story

Hear this and more stories in a personalized audio briefing.

Open The Chonkerton